SEC FORM 4

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

ROUSSEAU MICHAEL T

(Last)

(First)

(Middle)

ONE ST. JUDE MEDICAL DRIVE

(Street)

ST. PAUL

55117

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
ST JUDE MEDICAL, LLC [ STJ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Director, President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/04/2017

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/04/2017		D		46,779	D	⁽¹⁾	0	D
Common Stock	01/04/2017		D		19,618	D	⁽¹⁾	0	I⁽⁵⁾	Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Options (Right to Buy)	$38.59	01/04/2017		D			182,000	12/14/2010⁽²⁾	12/14/2017	Common Stock	182,000	⁽²⁾	0	I⁽⁵⁾	Family Trust
Stock Options (Right to Buy)	$41.65	01/04/2017		D			204,000	12/14/2011⁽²⁾	12/14/2018	Common Stock	204,000	⁽²⁾	0	I⁽⁵⁾	Family Trust
Stock Options (Right to Buy)	$34.96	01/04/2017		D			300,000	12/17/2012⁽²⁾	12/12/2019	Common Stock	300,000	⁽²⁾	0	I⁽⁵⁾	Family Trust
Stock Options (Right to Buy)	$35.27	01/04/2017		D			183,750	12/17/2013⁽²⁾	12/10/2020	Common Stock	183,750	⁽²⁾	0	I⁽⁵⁾	Family Trust
Stock Options (Right to Buy)	$35.27	01/04/2017		D			61,250	12/17/2013⁽²⁾	12/10/2020	Common Stock	61,250	⁽²⁾	0	D
Stock Options (Right to Buy)	$59.41	01/04/2017		D			74,570	12/17/2014⁽²⁾	12/10/2021	Common Stock	74,570	⁽²⁾	0	I⁽⁵⁾	Family Trust
Stock Options (Right to Buy)	$59.41	01/04/2017		D			74,570	12/17/2014⁽³⁾	12/10/2021	Common Stock	74,570	⁽³⁾	0	D
Restricted Stock Units	⁽⁴⁾	01/04/2017		D			4,474	⁽⁴⁾	⁽⁴⁾	Common Stock	4,474	⁽⁴⁾	0	D
Stock Options (Right to Buy)	$69.08	01/04/2017		D			108,444	12/17/2015⁽³⁾	12/08/2016	Common Stock	108,444	⁽³⁾	0	D
Stock Options (Right to Buy)	$69.08	01/04/2017		D			36,148	12/17/2015⁽²⁾	12/08/2022	Common Stock	36,148	⁽²⁾	0	I⁽⁵⁾	Family Trust
Restricted Stock Units	⁽⁴⁾	01/04/2017		D			8,214	⁽⁴⁾	⁽⁴⁾	Common Stock	8,214	⁽⁴⁾	0	D
Stock Options (Right to Buy)	$61.62	01/04/2017		D			348,888	12/17/2016⁽³⁾	12/07/2023	Common Stock	348,888	⁽³⁾	0	D
Restricted Stock Units	⁽⁴⁾	01/04/2017		D			27,789	⁽⁴⁾	⁽⁴⁾	Common Stock	27,789	⁽⁴⁾	0	D

Explanation of Responses:

1. Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock.

2. Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.

3. Each option provided for vesting in four equal installments on December 17 commencing one year after the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio.

4. Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio.

5. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

	/s/ Kashif Rashid, Attorney in Fact	01/06/2017
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.